Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weightIn the trial, Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefitsResults from the largest and longest Mounjaro trial to date reaffirm its established safety and tolerability profile INDIANAPOLIS, July 31, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today ann ...